The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and tolerability of tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma.
 
James Patrick Allison
Patents, Royalties, Other Intellectual Property - Inventor of a patent held by the University of California, Berkeley, and licensed to Bristol Meyers-Squibb; Inventor of a patent owned by Memorial Sloan-Kettering Cancer Center and licensed by Jounce Therapeutics
Efficacy, Toxicity, and Pharmacology of an Antisense Oligonucleotide Directed Against Protein Kinase C-? (ISIS 3521) Delivered as a 21 Day Continuous Intravenous Infusion in Patients with Recurrent High Grade Astrocytomas (HGA).
 
Padmanee Sharma
Stock and Other Ownership Interests - Evelo Therapeutics; Jounce Therapeutics; Jounce Therapeutics; Jounce Therapeutics (I); Kite, a Gilead company; Kite, a Gilead company; Kite, a Gilead company (I); Neon Therapeutics; Neon Therapeutics (I)
Consulting or Advisory Role - Amgen; Amgen (I); AstraZeneca; AstraZeneca (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); Constellation Pharmaceuticals; Constellation Pharmaceuticals (I); EMD Serono; EMD Serono (I); Evelo Therapeutics; Evelo Therapeutics (I); GlaxoSmithKline; GlaxoSmithKline (I); Jounce Therapeutics; Jounce Therapeutics (I); Kite, a Gilead company; Kite, a Gilead company (I); Neon Therapeutics; Neon Therapeutics (I)
Patents, Royalties, Other Intellectual Property - Own patent licensed to Jounce; Own patents licensed to BMS, Jounce & Merck (I)
 
Luc Dirix
No Relationships to Disclose
 
Filip Yves Francine Leon De Vos
Research Funding - Abbvie; Bristol-Myers Squibb; Novartis
Travel, Accommodations, Expenses - Amgen; Novartis; Roche
 
Lore Decoster
Research Funding - Boehringer Ingelheim; Roche
 
Renata Zaucha
Speakers' Bureau - Amgen; Bristol-Myers Squibb
Research Funding - AstraZeneca; Bristol-Myers Squibb
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche
 
Joon Oh Park
Honoraria - Celgene
Consulting or Advisory Role - Celgene
Speakers' Bureau - Celgene; Celgene; Celgene
Research Funding - AstraZeneca; Celgene
 
Ari M. Vanderwalde
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb
Research Funding - Amgen; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck; Millennium; Polynoma
 
Ritesh S. Kataria
Stock and Other Ownership Interests - AstraZeneca
 
Salvatore Ferro
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Gargi Patel
No Relationships to Disclose
 
Yong (Ben) Ben
Employment - AstraZeneca; BioAtla
Leadership - BioAtla
Stock and Other Ownership Interests - AstraZeneca; BioAtla
 
Do-Youn Oh
Consulting or Advisory Role - Debiopharm Group; Lilly; MSD; Roche
Research Funding - AstraZeneca